A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
Status:
Completed
Trial end date:
2016-05-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib)
administered to patients with chemoimmunotherapy-resistant follicular lymphoma (FL).